M038 SEVERE DUPILUMAB-ASSOCIATED HEAD AND NECK DERMATITIS WITH OCULAR INVOLVEMENT IN A TEN-YEAR-OLD WITH ATOPIC DERMATITIS

Abstract

Dupilumab-associated head and neck dermatitis (HND) is the term used to describe the new onset or exacerbation of head and neck erythema in patients receiving dupilumab for moderate-to-severe atopic dermatitis (AD). While not reported in phase three clinical trials, it was later documented in 10% of adults. An off-label trial of dupilumab in children found HDN in 5.4% of subjects. Since its approval for children six years and up, a dozen cases have been reported in children, most of them postpubertal.